Press
Releases

Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress

Written on November 28, 2022

Providence Therapeutics Appoints Judyanna Yu as Chief Financial Officer

Written on November 02, 2022

Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults

Written on October 19, 2022

Providence Therapeutics Signs Licensing Agreement with SickKids for Immunotargeting Technology

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2021 Achievement Awards Ceremony, Sir Michael Houghton Inducted Into Alberta Bioindustry Hall of Fame

Providence Therapeutics and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

Providence Therapeutics announces $ 2.118 Million USD in funding to support process development and validation of the PTX-COVID19-B program, which targets high quality mRNA COVID-19 vaccine to low-to middle-income countries at affordable prices.

Providence Therapeutics Announces Donna T. Ward, Ph.D., J.D. appointment to Board of Directors

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Providence Therapeutics Announces New Chief Development Officer and Chief Medical Officer

Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine

Providence Therapeutics Announces Jared Davis as President

Providence Therapeutics COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials

Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)

Northern RNA and Providence Therapeutics Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of Providence Therapeutics mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia

Providence Therapeutics Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial

Providence Therapeutics Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine

Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19